23.03.2021 14:28:20
|
Omeros Says First Patients Dosed With Narsoplimab In I-SPY COVID-19 Trial
(RTTNews) - Omeros Corp. (OMER) and Quantum Leap Healthcare Collaborative said that they began dosing of patients with narsoplimab in the I-SPY COVID-19 Trial. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative.
The trial will screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoid or reduce the duration of mechanical ventilation for critically ill COVID-19 patients.
Narsoplimab is Omeros' lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement. It is the only complement inhibitor invited to participate in the I-SPY COVID-19 Trial.
Narsoplimab has been administered under compassionate use to treat severely ill COVID-19 patients requiring mechanical ventilation, with impressive outcomes.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Omeros Corpmehr Nachrichten
Keine Nachrichten verfügbar. |